FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, particularly to ophthalmology, and can be used to reduce scarring in a subject with a keratoconjunctive disorder. To this end, the subject is administered a RARγ agonist in an amount effective to reduce scarring, wherein said RAR agonistγ is (E)-4-(2-{3-[(1H-pyrazol-1-yl)methyl]-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl}vinyl) benzoic acid, 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene acid, 3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetylamino]benzoic acid, oxime(2E)-3-(4-carboxyphenyl)-1-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-propen-1-one, 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid, ester or salt thereof. Method for inhibiting collagen degradation and/or collagen contraction, reducing tissue scarring on a conjunctiva and/or cornea in a subject with a keratoconjunctive disorder is also provided.
EFFECT: group of inventions ensures weakening of keratoconjunctive disorders, tissue scarring, suppression of collagen degradation.
21 cl, 6 dwg, 5 ex
